Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M DahlJoseph P RodgersWilliam U ShipleyM Dror MichaelsonChin-Lee WuWilliam ParkerAshesh B JaniFabio L CuryRichard S HudesJeff M MichalskiAlan C HartfordDaniel SongDeborah E CitrinTheodore G KarrisonHoward M SandlerFelix Y FengJason Alexander EfstathiouPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder. At 3 years, 88% of the patients remained free of cystectomy.
Keyphrases
- high grade
- phase ii
- low grade
- clinical trial
- end stage renal disease
- spinal cord injury
- open label
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- urinary tract
- prognostic factors
- papillary thyroid
- muscle invasive bladder cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- stem cells
- phase iii
- patient reported outcomes
- risk assessment
- human health
- combination therapy
- cell therapy
- lymph node metastasis
- childhood cancer
- replacement therapy